Effect of istradefylline on mood disorders in Parkinson's disease

Nagayama, Hiroshi; Kano, Osamu; Murakami, Hidetomo; Ono, Kenjiro; Hamada, Masayuki; Toda, Tatsushi; Sengoku, Renpei; Shimo, Yasushi; Hattori, Nobutaka

doi:10.1016/j.jns.2018.11.005

Cited by 39 publications

(25 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there needs to be evaluation of their potential antidepressant effects in models that reflect the pathology and biochemistry of the illness, and potentially also in major depression. One small-scale, open-label clinical study of the effects of istradefylline on mood disorders in PD has been undertaken [60]. As expected, administration of istradefylline over 12 weeks improved Unified Parkinson's Disease Rating Scale scores, consistent with its antiparkinsonian activity.…”

Section: Tablementioning

confidence: 55%

Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?

Jenner

Mori

Kanda

2020

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 55%

Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?

Jenner

Mori

Kanda

2020

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

“…Based on the ndings in this review, one could say with caution that rivastigmine (26), pramipexole (24), istradefylline (20), and selegiline combined with levodopa (27) are better in the treatment of apathy in PD than monotherapy with levodopa, DA or placebo (Table 3). These studies show signi cant outcomes in favor of the intervention treatment.…”

Section: Discussionmentioning

confidence: 99%

Pharmacological treatment of apathy in Parkinson’s disease, review of the literature

Overvliet¹,

Vlaar²,

Haan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Apathy is a highly challenging factor in the general treatment of patients with Parkinson’s disease (PD) and can present a major burden for caregivers. The objective of this study to answer the question of what is known about the current evidence-based pharmacological treatment of apathy, not combined with comorbid depression or dementia, in PD. Methods We searched for publications in online databases (PubMed, Embase.com, Cochrane Database of Systematic Reviews, CENTRAL and PsycInfo/Ebsco) and performed a review of the literature. Included trials were based on patients with PD, with a drug intervention and apathy as an outcome measurement. Patients with comorbid dementia, severe depression, or patients after deep brain stimulation were excluded. Results Out of 1767 articles, we included 10 articles with a total of 723 patients who received intervention and 311 patients who received placebo, standard care or were healthy controls. Combining the results of the studies with a focus on favourable significant outcomes and the risk of bias, we would advise rivastigmine as a treatment of apathy in patients with PD, and pramipexole or selegiline in PD patients with apathy without cognitive disturbance. An important limitation of this study is that the included studies show a broad heterogeneity. Conclusions Research is sparse on the topic of evidence-based pharmacological treatment for apathy in PD. Combining the results of the studies with a focus on favourable significant outcomes and the risk of bias, we would advise rivastigmine as a treatment of apathy in patients with PD, and pramipexole or selegiline in PD patients with apathy without cognitive disturbance.

show abstract

“…In an open-label trial including 30 PD individuals, the use of istradefylline (adenosine A2A receptor antagonist), an antiparkinsonian agent, significantly reduced levels of apathy (assessed using the Apathy scale) after a 12-week treatment period (Nagayama et al, 2019).…”

Section: Other Disordersmentioning

confidence: 99%

Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders

et al. 2020

View full text Add to dashboard Cite

Apathy is one of the most frequent behavioral disturbances in many neurodegenerative disorders and is known to have a negative impact on the disease progression, particularly in Alzheimer's disease. Therapeutic options are currently limited and non-pharmacological approaches should constitute first line treatments. Pharmacological agents likely to reduce apathy levels are lacking. The objective of the present article is to review recent pharmacological treatments for apathy in neurodegenerative disorders. The Pubmed database was searched with a particular focus on articles published as of January 2017. Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results. Treatment duration and samples sizes may have however decreased the validity of previous results. Ongoing studies involving more participants/treatment duration or distinct neural pathways may provide new insights in the treatment of apathy in neurodegenerative disorders.

show abstract

Effect of istradefylline on mood disorders in Parkinson's disease

Cited by 39 publications

References 37 publications

Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?

Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?

Pharmacological treatment of apathy in Parkinson’s disease, review of the literature

Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders

Contact Info

Product

Resources

About